October 24, 2013 I La Merie published in February 2007 for the first time a compilation of the annual sales of therapeutic proteins and antibodies. Since then, we released every year our list of TOP selling antibodies and proteins. You can find these annual reports published in our weekly newsletter R&D Pipeline News as a special edition in our online portal www.pipelinereview.com under FREE Reports.
We thought you might find it useful to have a look how annual sales of antibodies and proteins developed since 2006. We first prepared a table with the data for antibodies and found an amazing average/continuous annual growth rate of 18.9 % from 2006 to 2012. You can download the data at: http://pipelinereview.com/index.php/download?path=antibody%20sales%202006-2012.pdf
Or go to the menu FREE Reports / FREE Downloads at www.pipelinereview.com
Last year, i.e. 2012, antibody sales summed up US$ 64.6 bln and for the first time were higher than those of recombinant protein therapeutics. Please bear in mind minor errors in accuracy of the data due to currency exchange influences and incomplete publication of some data. But the overall picture is clear: antibodies sell well! And it is not only cancer and anti-TNF antibodies which make out of most of antibody sales. New antibodies are have emerged recently and are gaining in market shares. It can be expected that they will compensate for potential future losses of leading antibodies when biosimilar antibodies come up.